Adjuvant chemotherapy for invasive bladder cancer

Evidence Summaries

Level of Evidence = B
Adjuvant chemotherapy for invasive bladder cancer appears to improve survival.

A Cochrane review 1 included 6 studies with a total of 491 subjects. The overall hazard ratio for survival was 0.75 (95% CI 0.60 to 0.96, p=0.019), suggesting a 25% relative reduction in the risk of death for chemotherapy compared to that on control. The impact of trials that stopped early, of patients not receiving allocated treatments or not receiving salvage chemotherapy is unclear. The power of the meta-analysis is clearly limited.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison).

References

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006 Apr 19;(2):CD006018.  [PMID:16625650]


Copyright © 2019 Duodecim Medical Publications Limited.
Adjuvant chemotherapy for invasive bladder cancer is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.